Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to -blocker therapy in hypertension
Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to -blocker therapy in hypertension
复制标题
DOI：
10.1177/0300060514563151
复制
发表时间：
2015-06-01
影响因子：
1.6
通讯作者：
Xu, Jiasen
中科院分区：
文献类型：
--
作者：
Wu, Dingchang;Li, Ganyang;Xu, Jiasen
目的探讨1-肾上腺素能受体（ADRB 1）和细胞色素P450 2D 6（CYP 2D 6）基因多态性与β受体阻滞剂治疗高血压的关系。使用xTAG（R）液体芯片技术进行CYP 2D 6 100 C>T和ADRB 1 1165 G>C基因分型。通过广义线性模型拟合评估基因多态性与降压治疗结局之间的关联。收缩压下降10 mmHg即为有效治疗结果。ADRB 1和CYP 2D 6的突变等位基因频率分别为61.29%和58.60%。ADRB 1和CYP 2D 6基因多态性对治疗结果的影响之间没有显著的相互作用。突变型ADRB 1基因型（CC）纯合子患者的治疗结果优于突变型（GC）杂合子患者。结论ADRB 1 1165 G>C基因多态性和β受体阻滞剂治疗时间是影响β受体阻滞剂治疗效果的独立因素。这些发现表明，抗高血压治疗的选择应考虑患者的基因型。
Objective To investigate the associations between (1)-adrenergic receptor (ADRB1) and cytochrome P450 2D6 (CYP2D6) gene polymorphisms and -blocker treatment outcomes in patients with hypertension.Methods Chinese patients with essential hypertension were treated with the -blocker metoprolol and followed up for 12 weeks. xTAG (R) liquid-chip technology was used for CYP2D6 100C>T and ADRB1 1165G>C genotyping. Associations between gene polymorphisms and antihypertensive therapy outcomes were assessed by generalized linear model fitting. A decrease of 10mmHg in systolic blood pressure indicated an effective treatment outcome.Results A total of 93 patients were included in the study. Mutant allele frequencies of 61.29% and 58.60% were obtained for ADRB1 and CYP2D6, respectively. There was no significant interaction between the effects of ADRB1 and CYP2D6 gene polymorphisms on treatment outcome. Patients homozygous for the mutant ADRB1 genotype (CC) had better treatment outcomes than those heterozygous for the mutation (GC). Interestingly, -blocker treatment duration was an independent factor associated with treatment outcome.Conclusions The ADRB1 1165G>C gene polymorphism and -blocker treatment duration are independent factors associated with -blocker treatment outcome. These findings suggest that the selection of antihypertensive therapy should take into consideration the patient's genotype.